6. REFERENCES

1. Acbay O et al. (1996) Can metformin reduce insulin resistance in polycystic ovary syndrome? Fertil Steril 65 (5): 946

2. Adams J et al., 1986 Prevalence of polycistic ovaries in women with anovulation and idiopathic hirsutism. Br Med J 293: 355 

3. Albareda M et al., (2000): Assessments of insulin sensitivity and beta cells functions from measurements in the fasting state and an during glucose tolerance test. Diabetologia (43) : 1507

4. Anderson LA et al. (2002) The regulation of HSL and LPL expression by DHT and flutamide in human subcutaneous adipose tissue. Diabetes Obesity and Metabolism 4 (3): 209

5. Anonymous ( 1997) Report of the Export Committee on the Diagnosis and Classification of DM.   Diabetes Care 20: 1183-1197 

6. Arcadian S.A. et al. (2002) Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia /insulin resistance. J Clin Endocrinol Metab 87: 1555

7. Avignon A. et al. (1999) Assessment of insulin sensitivity from plasma insulin and glucose in the fasting or post oral glucose-load state. Int J Obes Relat Metab Disord. 23 (5):512

8. Bach LA   (1999) Insulin-like growth factor binding protein-6: the "forgotten" binding protein? Horm Metab Res   31 (2-3):   226

9. Barash IA et al.   (1996) Leptin is a metabolic signal to the reproductive system. Endocrinology 137 (7):   3144

10. Belli SH et al. (2004) Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome. Fertil Steril   81 (3): 624

11. Bergman R.N.,   (1997) New concepts in extracellular signaling for insulin action: the single gateway hypothesis. Recent Prog Horm Res.   52 : 359

12. Bringer J et al.   (1993) Body composition and regional fat distribution in polycystic syndrome. Ann New York Acad Sci   687:   115

13. Brzechffa R et al.   (1996) Serum immunoreactive leptin concentrations in women with polycystic ovary syndrome. J Clin Endocrinol Metab   81 (11):   4166

14. Burghen G.A. et al.   (1980) Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab   50:   113

15. Burkman RT   (1995) Oral contraceptives: an update. Hosp Pract (Off Ed)   30 (4):   85

16. Campo S   (1998) Ovulatory cycles, pregnancy outcome and complications after surgical treatment of polycystic ovary syndrome. Obstet Gynecol Surv   53:   297

17. Casimirri F et al.   (1997) Metformin improves insulin, body fat distribution and androgens in obese women with and without the polycystic ovary syndrome. Int J Obesity,   21   (suppl. 2):   61

18. Chapman IM et al.   (1997) Circulating leptin concentrations in polycystic ovary syndrome: relation to anthropometric and metabolic parameter. Clin Endocrinol (Oxford)   46:   175

19. Ciampelli et al.   (2005) Assessment of insulin sensitivity from measurements in the fasting state and during an oral glucose tolerance test in PCOS and menopausal patients. J Clin Endocrinol Metab   90 (3): 1398

20. Conn JJ et al.   (2000) The prevalence of polycystic ovaries in women with type 2 diabetes mellitus. Clin Endocrinol (Oxf).   52 (1):   81

21. Conway GS et al.   (1989) Heterogeneity of the polycystic ovary syndrome: clinical, endocrine, and ultrasound features in 556 patients.  Clin Endocrinol (Oxf)  30:   459

22. Coulam CB et al.   (1983) Chronic anovulation syndrome and associated neoplasia. Obstet Gynecol 61 (4):   403

23. Crave JC et al.   (1995) Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. J Clin Endocrinol Metab.   80:   2057

24. Dandona P et al.   (1983) Diarrhea and metformin in a diabetic clinic . Diabetes Care 6:   472

25. De Fronzo RA. et al.   (1991) Mechanism of metformin action in obese and lean non-insulin-dependent diabetic subjects. J Clin Endocrinol Metab   73:   1294

26. De Leo V et al. (2000) Effect of metformin on insulin-like growth factor (IGF) I and IGF-binding protein I in polycystic ovary syndrome. J Clin Endocrinol Metab 85 (4):   1598

27. Dejager et al.   (2001) Smaller LDL particle size in women with polycystic ovary syndrome compared to controls. Clin Endocrinol (Oxf)   54 (4):   455

28. Diamanti-Kandarakis E et al.   (1995) Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome. Metabolism: Clinical and Experimental,   44:   525

29. Diamond MP et al. (1991) Effect of acute physiological elevations of insulin on circulating androgen levels in normal women. J Clin Endocrinol Metab   72:   883

30. Dörner D (1998) Environment and gene dependent effetcs of hormones and neurotransmitters on brain development in mammals. In: Gies A, Wenzel A, Gahr M, editors. Effects of endocrine disrupters in the environment on neuronal development and behaviour. Berlin:   Umweltbundesamt 50:   71

31. Dörner G. (1996) Umwelthormone als Ursache lebenslanger Fehlfunktionen. Humboldt Spektrum 4: 12

32. Douchi, T et al.   (1995) Body fat distribution in women with polycystic ovary syndrome. Obstet Gynecol,   86:   516

33. Duleba AJ et al.   (1993) Insulin actions on ovarian steroidogenesis are not modulated by metformin. Hum Reprod   8:   1194

34. Dumesic DA et al.   (1997) Prenatal exposure of female rhesus monkeys to testosterone propionate increases serum luteinizing hormone levels in adulthood.  Fertil Steril   67:   155

35. Dunaif A (1997) Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev   18:   774

36. Dunaif A   (1987) Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab   65:   499

37. Dunaif A   (1990) Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab 70: 699

38. Dunaif A. et al.   (2001) Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). Am J Physiol   281:   392

39. Dunaif A et al.   (1996) The insulin sensitizing agent troglitazone improves metabolic and reproductive abnormalities in PCOS.  J Clin Endocrinol Metab   81:   3299

40. Dunaif, A & Finegood DT   (1996a) Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 81:   942

41. Dunn CJ, Peters DH   (1995) Metformin: a review of its pharmacological properties and therapeutic uses in non-insulin-dependent diabetes. Drugs 49 (5):   721

42. Eagleson CA.   (2002) Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab.   85 (11):   4047

43. Ehrmann DA   (1995a) Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest   96:   520

44. Ehrmann DA et al.   (1995) Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism. Endocr Rev   16:   322

45. Ehrmann DA et al.   (1997) Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab   82:   524

46. Eisner et al.   (2000) Timing of prenatal androgen excess determines differential impairment in insulin secretion and action in adult female rhesus monkeys. J Clin Endocrinol Metab   85:   1206

47. Ek I et al.   (2002) A unique defect in the regulation of visceral fat cell lipolysis in the polycystic ovary syndrome as an early link to insulin resistance. Diabetes   51 (2):   484

48. El-Biely MM and Habba M (2001) The use of metformin to augment the induction of ovulation in obese infertile patients with polycystic ovary syndrome. Middle East Fertil Soc J   6:   43

49. Erikson GF et al.   (1990) The effects of insulin and insulin-like growth factor-I and –II on estradiol production by granulosa cells of polycistic ovaries. J Clin Endocrinol Metab   70 : 894

50. Erturk E. et al.   (2004) Serum leptin levels correlate with obesity parameters but not with hyperinsulinism in women with polycystic ovary syndrome. Fertil Steril. 82 (5): 1364

51. Falcone T et al.   (1990) Androgen response to endogenous insulin secretion during the frequently sampled intravenous glucose tolerance test in normal and hyperandrogenic women. J Clin Endocrinol Metab   71:   1653

52. Ferriman D, Gallwey JD   (1961) Clinical assessment of body hair growth in women. J Clin Endocrinol Metab   21:   1440

53. Fleming R et al.   (2002) Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab   87 (2):   569

54. Fottner CD et al.   (1998) Regulation of steroidogenesis by insulin-like growth factors (IGFs) in adult human adrenocortical cells: IGF-I and, more potently, IGF-II preferentially enhance androgen biosynthesis through interaction with the IGF-I receptor and IGF-binding proteins. J Endocrinol   158:   409

55. Franks S   (1989) Polycystic ovary syndrome: a changing perspective. Clin Endocrinol (Oxf)   31 (1):   87

56. Franks S   (1995) Polycystic ovary syndrome. N Engl J Med   333:   853

57. Franks S. et al.,   (1999) Insulin action in the normal and polycystic ovary. Endocrinol. Metab. Clin. North Am.   28:   361

58. Gambineri A et al.   (2004) Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf)   60 (2):   241

59. Gharani et al.   (1997) Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. Hum Mol Genet   6   :397

60. Glueck CJ et al.   (1998) Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. Metabolism 48 (4):   511

61. Glueck CJ et al.   (2004) Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. Hum Reprod.   19   (6):   1323

62. Harborne RL et al.   (2005) Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J Clin Endocrinol Metab   May 10 as doi:10.1210/jc.2004-2283

63. Herold, Gerd: Innere Medizin,   Köln   2004 , p. 604

64. Holte J et al.   (1995) Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab   80:   2586

65. Hull MG (1987) Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. Gynecol Endocrinol   1 (3):   235

66. Ibanez L et al.   (2001) Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. J Clin Endocrinol Metab   86:   3595

67. Jacobs HS et al.   (1999) Leptin, polycystic ovaries and polycystic ovary syndrome. Hum Reprod Update   5 (2):   166

68. Jayagopal V et al.   (2003) The biological variation of testosterone and sex hormone-binding globulin (SHBG) in polycystic ovarian syndrome: implications for SHBG as a surrogate marker of insulin resistance. J Clin Endocrinol Metab 88:   1528

69. Katsuki A et al.   (1996) Acute and chronic regulation of serum sex hormone-binding globulin levels by plasma insulin concentrations in male noninsulin-dependent diabetes mellitus patients. J Clin Endocrinol Metab   81:   2515

70. Kazerooni T et al . (2003) Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome. Gynecol Endocrinol 17 (1):   5

71. Kiddy DS et al.   (1992) Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf.)   36:   105

72. Kirchengast S, Huber J   (2001) Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod   16 (6):   1255

73. Kocak M et al.   (2002) Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome. Fertil Steril   77 (1):   101

74. Kolodziejczyk B et al.   (2000) Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril   73 (6):   1149

75. Kowalska I et al.   (2001) Insulin, leptin, IGF-I and insulin-dependent protein concentrations after insulin-sensitizing therapy in obese women with polycystic ovary syndrome. Eur J Endocrinol   144 (5):   509

76. Krotkiewski M et al.   (2003) Effect of two modes of antiandrogen treatment on insulin sensitivity and serum leptin in women with PCOS. Gynecol Obstet Invest 55 (2):   88

77. Laughlin GA   (1997) Serum leptin levels in women with polycystic ovary syndrome: the role of insulin resistance/hyperinsulinemia. J Clin Endocrinol Metab 82:   1692

78. Lefebvre P et al.   (1997) Influences of weight, body fat patterning and nutrition on the management of PCOS. Hum Reprod   12 : 72

79. Legro RS   (1999) Polycystic ovary syndrome. Phenotype to genotype.Endocrinol Metab Clin North Am   28 (2):   379

80. Legro RS et al.   (2003) Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone. J Clin Endocrinol Metab   88 (11):   5137

81. Leroith D et al.   (1995) Molecuar and cellular aspects of insulin-like growth factor-I receptor. Endocr Rev   16:   143

82. Licinio J et al.   (1998) Synchronicity of frequently sampled, 24-h concentrations of circulating leptin, luteinizing hormone, and estradiol in healthy women. Med Sci   95 : 2541

83. Maciel GA et al.   (2004) Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin Fertil Steril   81 (2):   355

84. Maliqueo M et al.   (1999) Relationship between leptin and insulin sensitivity in patients with polycystic ovary syndrome. Med Clin Barc   113 (14):   526

85. Mantzoros CS et al.   (1997) Leptin concentrations in polycystic ovary syndrome. J Clin Endocrinol Metab   82:   1687

86. Marshall JC and Eagleson CA (1999) Neuroendocrine aspects of polycystic ovary syndrome. Endocrinol Metab Clin North Am   28:   295

87. Mather KJ et al.   (2000) Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity. Fertil Steril 73 (1):   150

88. Mehnert H (2001) Metformin, the rebirth of a biguanide: mechanism of action and place in the prevention and treatment of insulin resistance. Exp Clin Endocrinol Diabetes 109 (suppl 2):   259

89. Meirow D & Schenker JG   (1996) The link between female infertility and cancer: epidemiology and possible aetiologies. Hum Reprod Update   2 (1):   63

90. Michelmore K et al.   (2001) Clinical features in women with polycysic ovary syndrome: relationships to insulin sensitivity, insulin gene VNTR and birth weight. Clin Endocrinol   55:   439

91. Mikkelsen PB et al.   (2000) Effect of fat-reduced diets on 24-h energy expenditure: comparisons between animal protein, vegetable protein, and carbohydrate. Am J Clin Nutr   72:   1135

92. Moghetti et al.   (1996) Insulin infusion amplifies 17 α -hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity. J Clin Endocrinol Metab   81:   881

93. Moghetti P et al.   (2000) Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab   85:   139

94. Montague CT and O'Rahilly S   (2000) The perils of portliness: causes and consequences of visceral adiposity. Diabetes   49:   883

95. Morales AJ et al.   (1996) Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab   81 : 2854

96. Morin-Papunen LC et al.   (1998) Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril   69 (4):   691

97. Morin-Papunen LC et al.   (2000) Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab   85:   3161

98. Morin-Papunen LC et al.   (2003) Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab   88:   148

99. Nagamani M (1986) Hyperinsulinemia in hyperthecosis of the ovaries. American J Obstet Gynecol 15: 384

100. Nagamani M et al.   (1986) Hyperinsulinemia in hyperthecosis of the ovaries. Am J Obstet Gynecol   154 (2):   384

101. Nahum R et al.   (1995) Metabolic regulation of androgen production by human thecal cells in vitro. Hum Reprod   10 (1):   75

102. Nasseri S & Ledger WL   (2001) Clomiphene citrate in the twenty-first century. Human Fertil   4:   145

103. Nelson VL et al.   (2001 ) The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab   86: 5925

104. Nestler JE et al.   (1989) Suppression of serum insulin by diazoxide reduced serum testosterone levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 68:   1027

105. Nestler JE et al.   (1991) A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab   72:   83

106. Nestler JE et al.   (1998) Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab   83:   2001

107. Nestler JE & Jacubowicz DJ   (1996)  Decreases in ovarian cytochrome P450 c17 activity and serum free testosterone after reduction of insulin secretion in PCOS.  N Engl J Med   335:   617

108. Netler JE et al.   (1994) Effects of a reduction in circulating insulin by metformin on serum dehydroepiandrosterone sulfate in nondiabetic men. J Clin Endocrinol Metab 78 (3):   549

109. Ng EHY et al.   (2001) Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: A randomized, double-blinded placebo-controlled trial. Hum Reprod   16:   1625

110. Niwa K et al.   (2000) A case-control study of uterine endometrial cancer of pre- and post-menopausal women. Oncol Rep   7 (1):   89

111. Pasquali R et al.   (1993) Insulin and androgen relationships with abdominal body fat distribution in women with and without hyperandrogenism. Horm Res   39:   179

112. Pasquali R et al . (2000) Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without polycystic ovary syndrome. J Clin Endocrinol Metab   85:   2767

113. Peiris AN et al.   (1993) Relationship of insulin secretory pulses to sex hormone-binding globulin in normal men. J Clin Endocrinol Metab   76 (2):   279

114. Physicians’ Desk Reference,   2000,   Medical Economics Company   p. 831

115. Pierpoint T et al.   (1998) Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol   51 (7):   581

116. Pirwany IR et al.   (2001) Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clin Endocrinol (Oxf) 54 (4):   447

117. Poretsky L et al.   (1994) Insulin resistance, hypersecretion of LH and a dual defect hypothesis for the pathogenesis of PCOS.  Obstet Gynecol   84:   613

118. Prelevic GM et al.   (1990) Inhibitory effect of somatostatin on secretion of luteinizing hormone, ovarian steroids in polycystic ovary syndrome. Lancet   336:   900

119. Radziuk J   (2000) Insulin sensitivity and its measurement: structural commonalities among the methods. J Clin Endocrinol Metab   85:   4426

120. Rajkhowa M et al.   (1997) Altered composition of high density lipoproteins in women with the polycystic ovary syndrome. J Clin Endocrinol Metab   82 (10):   3389

121. Rebar R et al.   (1976) Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome.  J Clin Invest   57:   1320

122. Robinson S et al.   (1996) Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries. Clin Endocrinol (Oxf)   44 (3): 277

123. Robinson S et al.   (1993) The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries. Clin Endocrinol 39:   351

124. Rodin DA   (1998) Polycystic ovaries and associated metabolic abnormalities in Indian subcontinent Asian women. Clin Endocrinol   49:   91

125. Rosenfield RL   (1999) Ovarian and adrenal function in polycystic ovary syndrome. J Endocrinol Metab Clin North Am   28: 265

126. Salpeter, Shelley R.; Elizabeth Greyber; Gary A. Pasternak; Edwin E. Salpeter   (2003) Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis Arch Intern Med. 163: 2594-2602

127. Schildkraut JM et al.   (1996) Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet Gynecol   88 (4 Pt 1):   554

128. Schriock ED et al.   (1988) Divergent correlations of circulating dehydroepiandrosterone sulfate and testosterone with insulin levels and insulin receptor binding. J Clin Endocrinol Metab   66: 1329

129. Sepilian V, Nagamani M.   (2004) Effects of Rosiglitazone in Obese Women with Polycystic Ovary Syndrome and Severe Insulin Resistance. J Clin Endocrinol Metab.   Oct 13; [Epub ahead of print]

130. Sharp PS et al.   (1991) Correlation of plasma insulin and insulin-like growth factor-I with indices of androgen transport and metabolism in women with polycystic ovary syndrome. Clin Endocrinol (Oxf)   35:   253

131. Shoupe D et al.   (1983) Insulin resistance in polycystic ovary syndrome. Am J Obstet Gynecol 147 (5):   588

132. Sir-Petermann T et al.   (1999) Are circulating leptin and luteinizing hormone synchronized in patients with polycystic ovary syndrome? Hum Reprod   14:   1435

133. Solomon CG et al.   (2002) Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab   87:   2013

134. Steingold K et al.   (1987) Clinical and hormonal effects of chronic gonadotropin-releasing hormone agonist treatment in polycystic ovarian disease.  J Clin Endocrinol Metab   65:   773

135. Timor-Tritsch IE & Rotten S   (1998) Transvaginal Sonography. Elsevier.   Science Publishing Co, Inc.,   New York

136. Ünlühizarci K   (1999b) The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome. Clin Endocrinol   51:   231

137. Vandermolen DT et al.   (2001) Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril   75 (2):   310

138. Velasquez EM et al. (1994) Metformin therapy in polycystic ovary sindrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism   43:   647

139. Von Eckardsein A   (1998) Androgens, cardiovascular risk factors and atherosclerosis. In: Testosterone: Action, Deficiency, Substitution (eds E. Nieschlag and H.M Behre), Springer   pp. 229-257.

140. Waterworth DM et al.   (1997) Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome. Lancet   349:   986

141. Wheeler MJ (1995) The determination of bio-available testosterone. Ann Clin Biochem   32:   345

142. WHO   (1997) Preventing and managing the global epidemic. Report of a WHO consultation on obesity.   Geneva:   WHO/NUT/NCD/98.1

143. Wild RA   (2002) Long-term health consequences of PCOS. Hum Reprod Update 8 (3):   231

144. Willis D & Franks S   (1995) Insulin action in human granulosa cells from normal and polycystic ovaries is mediated by the insulin receptor and not the type-I insulin-like growth factor receptor. J Clin Endocrinol Metab   80 : 3788

145. Witters LA   (2001) The blooming of the French lilac. J Clin Invest   108:   1105

146. Zhou GR   (2002) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest   108: 1167–1174.


© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 4.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML generated:
10.04.2008